Table 3.

Pharmacological interactions of the drugs tested in COVID-19 with the most common antineoplastic drugs.

Anti-covid19	Interaction	Side effects
Azithromycin	Regorafenib	Therapeutic effect reduction
Azithromycin	Vinblastina	Increased serum levels of P-glycoprotein;
		Increased toxicity (neutropenia, myalgias, constipation)
Chloroquine	Doxorubicina	cardiomyopathy or conduction system abnormalities
Chloroquine	Taxanes	Increase in Plasma concentrations
Chloroquine	Trastuzumab	cardiomyopathy or conduction system abnormalities
Anakinra	Fluorouracile	Increased immunosuppressive action
Anakinra	Durvalumab	Therapeutic effect reduction
Emapalumab, Sarilumab	no interactions with antineoplastic drugs
Favipiravir	Enzalutamide	Interference with cytochromes: reduce efficacy of antivirals
Lopinavir
Ritonavir
Ribavirin
Umifenovir